Advertisement
Advertisement
RLYB
Rallybio Corporation Common Stock
8.55
USDSponsored
-0.12
-1.37%
Mar 25, 15:59 UTC -4
Closed
After-Market
8.60
+0.05
+0.57%
RLYB Earnings Reports
Positive Surprise Ratio
RLYB beat 15 of 19 last estimates.
79%
Next Report
Date of Next Report
--
Estimate for Q-- -- (Revenue/ EPS)
--
/--
Implied change from Q4 25 (Revenue/ EPS)
--
/--
Implied change from Q-- -- (Revenue/ EPS)
--
/--
Rallybio Corporation Common Stock earnings per share and revenue
On Mar 16, 2026, RLYB reported earnings of -1.03 USD per share (EPS) for Q4 25, beating the estimate of -1.19 USD, resulting in a 13.94% surprise. Revenue reached 222.00 thousand, compared to an expected 136.00 thousand, with a 63.24% difference. The market reacted with a -3.01% price change (close before vs. close after earnings).
Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Dyadic International, Inc.
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.04
Actual
-$0.06
Surprise
-30.72%
TELA Bio, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.16
Surprise
+14.12%
BioCardia, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.17
Actual
-$0.06
Surprise
+65.40%
Celcuity Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$1.06
Actual
-$0.97
Surprise
+8.72%
Precigen, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.01
Surprise
+88.24%
Absci Corporation Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.19
Actual
-$0.23
Surprise
-16.04%
Candel Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.25
Actual
-$0.54
Surprise
-115.31%
LENZ Therapeutics, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.99
Actual
-$1.15
Surprise
-17.10%
Fennec Pharmaceuticals Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
$0.03
Actual
-$0.11
Surprise
-408.12%
Equillium, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.06
Actual
-$0.04
Surprise
+35.28%
FAQ
What were Rallybio Corporation Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Rallybio Corporation Common Stock reported EPS of -$1.03, beating estimates by 13.94%, and revenue of $222.00K, 63.24% above expectations.
How did the market react to Rallybio Corporation Common Stock's Q4 2025 earnings?
The stock price moved down -3.01%, changed from $9.65 before the earnings release to $9.36 the day after.
When is Rallybio Corporation Common Stock expected to report next?
The next earning report is scheduled for --.
What are the forecasts for Rallybio Corporation Common Stock's next earnings report?
Based on --
analysts, Rallybio Corporation Common Stock is expected to report EPS of -- and revenue of -- for Q-- --.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement